--- title: "拜瑪林制藥 (BMRN.US) — 財務報表" type: "Symbol" locale: "zh-HK" url: "https://longbridge.com/zh-HK/quote/BMRN.US/norm.md" symbol: "BMRN.US" name: "拜瑪林制藥" parent: "https://longbridge.com/zh-HK/quote/BMRN.US.md" datetime: "2026-05-19T23:28:53.994Z" locales: - [en](https://longbridge.com/en/quote/BMRN.US/norm.md) - [zh-CN](https://longbridge.com/zh-CN/quote/BMRN.US/norm.md) - [zh-HK](https://longbridge.com/zh-HK/quote/BMRN.US/norm.md) --- # 拜瑪林制藥 (BMRN.US) — 財務報表 ## 損益表 (USD) | 指標 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | 每股收益 | 0.5431 | -0.2423 | -0.1601 | 1.23 | 0.9544 | | ROE | 6.86% | -3.07% | -2.04% | 16.28% | 12.97% | | 營業收入 | 766.21M | 874.57M | 776.13M | 825.41M | 745.14M | | 凈利潤 | 105.53M | -46.57M | -30.74M | 240.53M | 185.69M | | 營業利潤 | 137.95M | 196.64M | -46.69M | 276.89M | 223.89M | | 毛利率 | 51.21% | 60.10% | 29.19% | 62.27% | 58.36% | | 凈利率 | 13.77% | -5.33% | -3.96% | 29.14% | 24.92% | | 利潤含金量 | 62.52% | 197.35% | -12.66% | 149.45% | 128.38% | ## 資產負債表 (USD) | 指標 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | 資產與負債 | 8.59B | 7.59B | 7.61B | 7.46B | 7.15B | | 權益乘數 | 1.38 | 1.25 | 1.26 | 1.24 | 1.23 | | 每股凈資產 | 32.14 | 31.65 | 31.53 | 31.39 | 30.21 | | 資產周轉率 | 0.4120 | 0.4418 | 0.4278 | 0.4219 | 0.4209 | | 現金及短投 | 2.22B | 1.56B | 1.48B | 1.43B | 1.27B | | 存貨與應收 | 1.27B | 1.30B | 1.38B | 1.34B | 1.27B | | 長期投資 | 958.07M | 991.80M | 1.04B | 1.03B | 1.03B | | 凈債務 | -782.83M | -917.74M | -873.60M | -828.26M | -670.38M | ## 現金流量表 (USD) | 指標 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | | --- | --- | --- | --- | --- | --- | | 經營現金流 | 220.65M | 99.64M | 368.69M | 185.27M | 174.39M | | 投資現金流 | 725.53M | -42.45M | -330.96M | -12.59M | -28.24M | | 融資現金流 | 813.17M | 3.16M | -2.17M | -4.60M | -38.78M | | 自由現金流 | 168.90M | 90.47M | 115.64M | 98.78M | 104.58M | | 現金流充裕率 | 1054.59% | 244.69% | 1296.04% | 1083.39% | 1040.04% | | 舉債與償債 | 850.00M | - | - | - | - | | 資本支出 | -20.92M | -40.72M | -28.45M | -17.10M | -16.77M |